Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
Primary Industries
- Drugs
- Disease
- Therapeutic
- Pain
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 372405
(i) Research, develop or Commercialize, or have researched, developed or commercialized the Licensed Products;
(ii) Make and use the applicable Licensed Products;
(iii) Have made the applicable Licensed Products in accordance with this agreement;
(iv) Sell, offer for sale, promote and market the applicable Licensed Products (by itself, an Affiliate or through one or more Third Parties); and
(v) Import or have imported each Licensed Product.
Iferanserin means the serotonin (5-HT2) receptor antagonist S-MPEC (iferanserin (INN) = (E)-2’-{2- [(2S)-l-methyl-2-piperidyl]ethyl}cinnamanilide serotonin receptor antagonist C23H28N2O, CAS 58754-46- 4). The definition includes all its various chemical forms, including derivatives acids, bases, esters, salts, isomers, enantiomers, pro-drug forms, metabolites, hydrates, solvates, polymorphs and degradants thereof in crystal, powder or other form and improvements, including new formulations and combinations and in addition, any back-up compounds to be provided by Licensor.
Licensor Patents means the (i) Patents listed
5,780,487 – S-2-[2-(1-methyl-2-piperidyl) ethyl] cinnamanilide
5,266,571 – Treatment of hemorrhoids with 5-HT.sub.2 antagonists
5,605,902 – 5-HT.sub.2 receptor antagonist compositions useful in treating venous conditions
Iferanserin is a drug which acts as a selective 5-HT2A receptor antagonist. It is under development as an intra-rectal formulation for the treatment of hemorrhoid disease, and as of February 2012, is in phase IIb clinical trials.
Anorectal conditions affect the anus and rectum. Fissures, fistulas, condyloma and hemorrhoids are among the most common anorectal conditions. In some cases, symptoms like pain, itching, burning, bleeding and/or swelling can significantly affect a patient's lifestyle.
IPSCIO Record ID: 249736
Bicifadine (DOV-220075) is a nonopioid analgesic. It is an inhibitor of both the norepinephrine and serotonin transporters and an NMDA antagonist with a non-narcotic profile. Bicifadine was shown to have potent analgesic activity in vivo and was chosen for further development for the treatment of pain.
IPSCIO Record ID: 372521
Licensee has the right to develop and commercialize the PET Ligand as set forth.
Licensor patents and technology relate to Imidazole Derivatives. The invention relates to novel Imidazole Derivatives which are NMDA receptor subtype specific blockers, useful in the treatment of acute forms of neurodegeneration (stroke, brain trauma) and of chronic forms of neurodegeneration ( Alzheimers disease, Parkinson, Huntingtons disease, ALS).
The products covered by the License Agreement are xO0678867; xO0693960; xO4378536; xO4394127; xO0631908; and, xO0717626.
The term Compound shall mean any of xO-0631908, xO-0678867, xO-0693960, xO4378536, x0-4394127, xO-0717626 and other compound structures Covered by the patent applications and patents for NMDA-2B receptor antagonists listed to the Agreement, including their salts, polymorphs, crystal forms, esters, hydrates, solvates, chelates, clathrates, metabolites that are NMDA-2B receptor antagonists, pro-drugs, isomers and enantiomers.
The term EVT 101 shall mean xO-4394127.
The term EVT 103 shall mean xO-0717626.
The term PET Ligand shall mean a Compound, with the exception of EVT 101 and EVT 103,
appropriately labelled for use in positron emission tomography for the specific labelling of NMDA NR2B subunit containing receptors in vivo.
EVT 100 family) for the treatment of a variety of CNS disorders such as Alzheimer’s disease, neuropathic pain and Parkinson’s Disease.